Topic

Cancer

11
Feb
2020

The Cell Therapy Puzzle: Jane Grogan on The Long Run

Today’s guest on The Long Run is Jane Grogan. Jane is the chief scientific officer of South San Francisco-based Arsenal Bio. Like the name suggests, Arsenal is pulling together a stockpile of potent tools of modern biology. As the company describes itself: Arsenal will integrate technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and...
Read More
21
Aug
2019

An Unforgettable Experience: The Kilimanjaro Climb to Fight Cancer Yearbook

The Kilimanjaro Climb to Fight Cancer was a marvelous experience. In every way. Weeks later, I’m still absorbing what it means to scientists at Fred Hutch, and to the biotech community. To start, consider the numbers: Our team of 27 climbers raised $1,587,475 for cancer research More than 2,200 donors contributed from around the country 33 sponsors supported the cause...
Read More
11
Jul
2019

Better Cancer Treatment Through Better Information: Cindy Perettie on The Long Run

Today’s guest on The Long Run is Cindy Perettie. Cindy is the CEO of Cambridge, Mass.-based Foundation Medicine. This company does genomic analysis on tumors. If you know more of this molecular nitty-gritty information – things like the underlying gene mutations that send cancer cells into out-of-control growth sprees – then you ought to occasionally come up with more effective...
Read More
9
Apr
2019

The Road Less Traveled in Glycoscience: Carolyn Bertozzi on The Long Run

Today’s guest on The Long Run is Carolyn Bertozzi. She is a professor of chemistry at Stanford University, and an entrepreneur. Her research is focused on glycans – the beautiful and bewilderingly complicated sugar molecule structures attached to proteins. These carbohydrates are often underappreciated by biologists, and “orthogonal” to the way many think. But glycans are known to play a...
Read More
27
Feb
2019

Staying Resilient, Finding a Way Forward: Julia Owens on The Long Run

Julia Owens is today’s guest on The Long Run. Owens is the CEO of Ann Arbor, Michigan-based Millendo Therapeutics. This company develops drugs for rare endocrine disorders. Prader-Willi syndrome, a terrible genetic disorder that causes young people to develop voracious appetites and which leads to severe obesity, is the focus of the company’s lead drug candidate. It’s entering a pivotal...
Read More
6
Feb
2019

Get Tickets Now: The Cancer Summit Series is Coming to Boston, SF, Seattle

We live in a time of tremendous possibility for cancer R&D. Checkpoint inhibitors, cell therapies, molecular diagnostics that catch cancer early and can guide effective custom treatment – these fields are brimming with progress. All were considered speculative at best a decade ago. The science has never been more promising. Yet pricing and access to this new world of cancer...
Read More
20
Dec
2018

Relay Therapeutics Hauls in $400M to Push Frontier in Computational Drug Discovery

Computers have been overhyped as tools of drug discovery for 15-20 years. But things have started turning in the right direction the past couple years, judging from recent bets by a few perspicacious investors. The latest example: Relay Therapeutics. Cambridge, Mass.-based Relay is announcing today it has raised a $400 million Series C financing heavy on private-public crossover investors. SoftBank...
Read More
12
Dec
2018

First Everest, Now Kilimanjaro: Climb With Me and a Great Biotech Team to Fight Cancer

Summiting the highest peak in the world and raising $340,000 for cancer research at Fred Hutch was the start. It was the start of something bigger. Today, I’m overjoyed to say that an outstanding team of biotech executives and investors will join me on the Kilimanjaro Climb to Fight Cancer. This will be a 7-day expedition to the summit of...
Read More
1 2 3 5